Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | BRS3 | P32247 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23514716 | 0.88 | CYP2A6 (0.59) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL8340357 | 0.86 | CYP2A6 (0.57) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL13878057 | 0.86 | CYP2A6 (0.67) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL13003924 | 0.85 | MKNK1 (0.56) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL10035334 | 0.85 | MKNK1 (0.49) | MKNK1MKNK2CYP2A6CYP3A4CYP19A1 | |
| SCHEMBL14732763 | 0.83 | EPHX2 (0.62) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL10035322 | 0.83 | MKNK1 (0.47) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL10035347 | 0.83 | MKNK1 (0.47) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL23919252 | 0.82 | CYP2A6 (0.53) | MKNK1MKNK2CYP2A6CYP3A4ALDH1A1 | |
| SCHEMBL24867289 | 0.82 | GPR55 (0.50) | MKNK1MKNK2CYP2A6RAB9ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20210315876-A1 | METHODS FOR REVERSING HIV LATENCY USING BAF COMPLEX MODULATING COMPOUNDS | PURDUE RESEARCH FOUNDATION | 2021-10-14 | — | — | US | disclosed |
| EP-3380471-B1 | TETRAHYDRO-8H-PYRIDO[1,2-A]PYRAZINE-8-ONES AS COMT INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | LIEBER INST INC DBA LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | LIEBER INST INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200255416-A1 | BAF Complex Modulating Compounds and Methods of Using the Same | THE BOARD OF TRUSTEES OF LELAND STANFORD JUNIOR UNIVERSITY | 2020-08-13 | — | — | US | disclosed |
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-9802904-B2 | Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802904-B2 | Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150344443-A1 | INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2015-12-03 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071404-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | MKNK1 284/4885MKNK2 219/4885CYP2A6 3670/4885 |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | COMT, PNMT, HNMT | MKNK1 1977/4885MKNK2 1954/4885CYP2A6 178/4885 |
| US-20150344443-A1 | INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF | USP1, UHRF1, UBQLN1 | MKNK1 2355/4885MKNK2 2451/4885CYP2A6 2859/4885 |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | MKNK1 3457/4885MKNK2 3802/4885CYP2A6 150/4885 |
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | PPID, PPIF, PPIL1 | MKNK1 1254/4885MKNK2 2138/4885CYP2A6 682/4885 |
| US-20210315876-A1 | METHODS FOR REVERSING HIV LATENCY USING BAF COMPLEX MODULATING COMPOUNDS | CHD1L, SMARCC1, CHD1 | MKNK1 2135/4885MKNK2 2769/4885CYP2A6 3991/4885 |
| US-10934283-B2 | COMT inhibiting methods and compositions | COMT, MAOB, MAOA | MKNK1 2166/4885MKNK2 1784/4885CYP2A6 92/4885 |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | MKNK1 4445/4885MKNK2 4492/4885CYP2A6 58/4885 |
| US-20200255416-A1 | BAF Complex Modulating Compounds and Methods of Using the Same | SMARCC1, SMARCC2, ATRIP | MKNK1 725/4885MKNK2 864/4885CYP2A6 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.